CPT Code Overview

CPT 81463 represents a targeted genomic sequence analysis panel for solid organ neoplasms, focusing on DNA analysis of 5 to 50 genes. This procedure is classified under Pathology and Laboratory services and is typically performed in an Independent Laboratory setting (POS 81). The test is designed to provide detailed genetic information relevant to the diagnosis and management of solid organ tumors, supporting precision medicine approaches in oncology.

Clinical Context

A patient diagnosed with a malignant neoplasm of the gastrointestinal tract, such as the small intestine, colon, rectum, or anal canal, is referred for advanced molecular testing. The treating oncologist requests a targeted genomic sequence analysis panel to identify mutations in 5-50 genes relevant to solid organ neoplasms. The specimen, typically a tissue biopsy from the tumor, is sent to an independent laboratory (Place of Service 81). A pathologist specializing in molecular genetic pathology oversees the DNA analysis, which assists in guiding targeted therapy and prognosis. The workflow involves specimen collection, laboratory processing, genomic sequencing, and interpretation of results by a qualified pathologist.

Coding Specifications

• Modifiers:

  • Modifier 26: Used when reporting only the professional component of the laboratory service, such as interpretation of results by a pathologist.
  • Modifier 59: Indicates a distinct procedural service, used when the genomic panel is performed separately from other procedures.

• Provider Taxonomies:

These taxonomies represent providers specializing in laboratory medicine, molecular genetic pathology, and anatomic pathology.

Related Diagnoses

• C17.0–C17.9: Malignant neoplasm of duodenum through malignant neoplasm of small intestine, unspecified

  • Relevant for patients with tumors in the small intestine, where genomic analysis may guide therapy.

• C18.0–C19: Malignant neoplasm of cecum through malignant neoplasm of rectosigmoid junction

  • Applies to colorectal cancers, which are frequently evaluated with targeted genomic panels.

• C20: Malignant neoplasm of rectum

  • Indicates rectal cancer, a common indication for molecular testing.

• C21.1: Malignant neoplasm of anal canal

  • Used for anal canal tumors, where genomic profiling can inform treatment options.

• C21.2: Malignant neoplasm of cloacogenic zone

  • Relevant for rare tumors in the cloacogenic zone, benefiting from targeted gene analysis.

• C21.8: Malignant neoplasm of overlapping sites of rectum, anus and anal canal

  • For tumors spanning multiple sites, genomic analysis helps clarify tumor biology.

• C7A.020–C7A.026: Malignant carcinoid tumor of appendix through malignant carcinoid tumor of rectum

  • Applies to neuroendocrine tumors, where molecular testing may influence management.

Related CPT Codes

• 81445: Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, 5-50 genes

  • Closely related to 81463, often used as an alternative or in similar clinical scenarios for genomic testing of solid organ neoplasms.

• 88342: Immunohistochemistry or immunocytochemistry, per specimen

  • Used to evaluate protein expression in tumor tissue, commonly performed alongside genomic sequencing to provide complementary diagnostic information.

• 88341: Immunohistochemistry or immunocytochemistry, each additional single antibody stain procedure

  • Used when multiple antibody stains are required, often in conjunction with 88342.

• 88360: Morphometric analysis, tumor immunohistochemistry

  • Provides quantitative analysis of immunohistochemical stains, supporting molecular findings from 81463.

• 81210: BRAF gene analysis, V600E variant

  • Specific gene analysis that may be included in the panel tested by 81463, or ordered separately when clinically indicated.

These codes are commonly used together in comprehensive tumor profiling or as alternatives depending on the clinical need.

National mean rates for CPT code 81463 among commercial payers show that UnitedHealth Group has the highest average reimbursement at $1,070.37, followed by Aetna at $1,016.15, and Blue Cross Blue Shield at $931.32. Cigna's mean rate is notably lower at $674.03. The BUCA average, representing the combined commercial benchmark, stands at $991.43. Medicare rates are not available in the input for comparison.

Rate dispersion varies significantly across payers. Cigna exhibits the widest spread, with a difference of $1,308.17 between its 75th and 25th percentiles, indicating substantial variability in contracted rates. Blue Cross Blue Shield also shows a broad range of $830.00. In contrast, Aetna has the tightest range at $398.25, suggesting more consistent reimbursement levels. The table and chart below present the full breakdown of national benchmarks for each payer.